Search
Search Results
-
Sacubitril/Valsartan in der Primärtherapie der Herzinsuffizienz mit reduzierter Ejektionsfraktion (HFrEF)
Sacubitril/Valsartan are recommended by all guidelines worldwide as the primary drug treatment of heart failure with reduced ejection fraction...
-
Sacubitril/valsartan and the risk of incident dementia in heart failure: a nationwide propensity-matched cohort study
BackgroundSacubitril acts to inhibit neprilysin and as neprilysin is involved in amyloid-beta degradation in the central nervous system, and there is...
-
Efficacy and safety of sacubitril/allisartan for the treatment of primary hypertension: a phase 2 randomized, double-blind study
This randomized, double-blind phase 2 study assessed the efficacy and safety of sacubitril/allisartan, an angiotensin receptor neprilysin inhibitor,...
-
Sacubitril/valsartan inhibits the proliferation of vascular smooth muscle cells through notch signaling and ERK1/2 pathway
AimsTo explore the role and mechanism of Notch signaling and ERK1/2 pathway in the inhibitory effect of sacubitril/valsartan on the proliferation of...
-
Left ventricular reverse remodeling following initiation of sacubitril/valsartan for heart failure with reduced ejection fraction and low blood pressure
Sacubitril/valsartan has become an important first-line drug for symptomatic heart failure (HF) patients, especially with left ventricular (LV)...
-
Functional changes in the heart after sacubitril/valsartan use in 5 hemodialysis patients with hypertension. Case report
The purpose of this report is to describe the efficacy of sacubitril/valsartan in 5 hemodialysis patients with hypertension, including a patient with...
-
The Effects of Sacubitril/Valsartan Compared to Olmesartan on the Blood Pressure and Glucolipid Metabolism in DM Patients with Primary Hypertension
PurposeGiven the beneficial effects of sacubitril/valsartan on blood pressure generally, this study investigates its antihypertension effects in...
-
The efficacy and safety of sacubitril/valsartan in chronic kidney disease: a systematic review and meta-analysis
BackgroundSacubitril/valsartan, a new pharmacological class of angiotensin receptor neprilysin inhibitor, is beneficial to heart failure through...
-
Network meta-analysis of sacubitril/valsartan for the treatment of essential hypertension
AimSacubitril/valsartan has been demonstrated to reduce blood pressure in hypertensive patients, but the best dose remains unclear. We performed this...
-
Acute Effects of Sacubitril/Valsartan with Initial Initiation in Pediatric Patients in the Cardiac Intensive Care Unit
There are very few objectively studied and proven medical interventions for the management of pediatric heart failure. Due to improvement in...
-
Sacubitril/Valsartan in Dialysis Patients: Update on Current Perspectives
Sacubitril/Valsartan is a combination of neprilysin inhibitor and angiotensin II receptor blocker that proved its own efficacy and safety in heart...
-
Different Doses of Sacubitril/Valsartan Compared with Olmesartan in Patients with Essential Hypertension: A Systematic Review and Meta-Analysis
IntroductionSince sacubitril/valsartan (LCZ696) has neprilysin inhibition and angiotensin receptor-blocking properties, it is anticipated to have...
-
Sacubitril/Valsartan for Heart Failure with Preserved Ejection Fraction: A Cost-Effectiveness Analysis from the Perspective of the Chinese Healthcare System
Background and ObjectivesSacubitril/valsartan has shown effectiveness in reducing hospitalization compared with valsartan in HFpEF patients with...
-
Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease
BackgroundImpaired renal function is frequently observed in patients with heart failure and reduced ejection fraction (HFrEF). The differential...
-
Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction
BackgroundAngiotensin receptor blocker and a neprilysin inhibitor (ARNI) has emerged as an innovative therapy for patients of heart failure with...
